| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 136.3 | 93.7 | 64.6 |
| Other income | 2.5 | 1.1 | 3.5 |
| Total income | 138.8 | 94.8 | 68.2 |
| Profit before exceptional items & tax | 14.0 | -1.5 | -7.3 |
| Profit before tax | 14.0 | -1.5 | -7.3 |
| Net profit | 11.8 | -3.6 | -8.6 |
| Operating margin | 10.1% | -1.6% | -10.7% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | +111.00% |
|---|---|
| Operating profit, year on year | +206.50% |
| Operating profit, quarter on quarter | +542.30% |
BSE results filing, NSE: BPLPHARMA. Figures extracted from the filing.
Bharat Parenterals Ltd: key numbers
- Share price
- ₹1,938.05
- Market cap
- ₹1,336 Cr
- Revenue (annual)
- ₹345.4 Cr
- Net profit (annual)
- ₹-8.19 Cr
- P/E (TTM)
- -86.7×Sector 46.1×
- Promoter holding
- 67.20%+0.00% QoQ
- FII holding
- 0.11%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Bharat Parenterals Ltd
All →Bharat Parenterals Investor Presentation: Key Takeaways
Q2 FY27 consolidated revenue ₹136.3 Cr (+110.9% YoY), EBITDA ₹23.6 Cr (17.3%), PAT ₹11.8 Cr; Innoxel turned profitable.
Bharat Parenterals Board Meeting Date
Bharat Parenterals will hold a board meeting on October 29, 2026 to consider unaudited standalone and consolidated results. Trading window has been closed since October 1, 2026.
Bharat Parenterals Annual General Meeting
Bharat Parenterals held an EGM via video conferencing on October 23, 2026. Members considered a preferential equity issue and Section 186 investment and guarantee limits.
Bharat Parenterals Business Update
Innoxel Lifesciences, a Bharat Parenterals subsidiary, began U.S. commercial supply of its first CMO product. This adds recurring manufacturing revenue to its existing licensing income.
Bharat Parenterals Preferential Issue
Bharat Parenterals filed a corrigendum to its EGM notice for a preferential issue exceeding ₹100 Crore. It adds a Crisil monitoring agency disclosure per BSE direction.
Bharat Parenterals Other Announcement
Bharat Parenterals Ltd filed its quarterly shareholding pattern for the period ending September 30, 2026, as per regulatory requirements.